DRUG DISCOVERY

Thomas Spector, Ph.D.

 

• HOME
• DRUG DEVELOPMENT
  • Expert Witness
• MEDICAL WRITING
• CURRICULUM VITAE
• Contact Dr. Spector

 

As International Vice President of Cancer Research at Glaxo Wellcome and Associate Director of Experimental Therapy and Principal Scientist at Burroughs Wellcome, Dr. Spector's drug discovery experience spanned a broad range of therapeutic areas.

These include:

 

• All Aspects of CANCER THERAPY
• ANTIVIRAL AGENTS
• CARDIOVASCULAR
• OTHER ANTIINFECTIVE AGENTS
• PHARMACODYNAMIC AGENTS

Select 'DRUG DEVELOPMENT' above for discriptions of discoveries that entered into Development.

Dr. Spector's personal research mainly involved drug interactions with chemotherapeutically important enzymes. The research generally probed the enzymes' mechanism as a basis to understand and design active agents. He is particularly interested in tight-binding or inactivating enzyme inhibitors. His research group discovered inactivators of several key enzymes. One inactivator, eniluracil, is in Phase III clinical trials as a potentiator of 5-fluorouracil, a cancer chemotherapy agent. The combination therapy (Cytofuran®) is being tested against breast, colorectal, pancreatic, head and neck, and hepatocellular tumors.